Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit .SAN DIEGO, Oct. 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 12, 2024, at 8:00 a.m. ET to report third quarter 2024 financial results and discuss recent business highlights.
圣地亚哥，2024年10月29日 /美通社/ -- 爱文思控股（Nasdaq：HRTX）（"爱文思"或"公司"），一家商业生物技术公司，今天宣布该公司将于2024年11月12日星期二上午8:00举行电话会议和现场网络直播，报告2024年第三季度财务业绩并讨论最近的业务亮点。
The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron's website at . An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.
可以通过以下注册链接来电话接入电话会议，该链接将提供参与者拨入详细信息。为避免延迟，我们鼓励参与者提前十五分钟拨入电话会议。电话会议也可通过爱文思网站的投资者关系部分进行网络直播。电话会议和网络直播的存档也将在电话会议结束后的60天内通过爱文思公司网站提供。
About Heron Therapeutics, Inc.
关于Heron Therapeutics，Inc。
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit .
海瑞恩生物技术公司是一家商业化阶段的生物技术公司，专注于通过开发和商业化改善医疗保健的治疗创新，改善患者的生活。我们拥有先进的科学、专利技术和创新的药物研发方法，已经成功研发了一系列的产品，旨在推动急性护理和肿瘤患者的医疗保健水平。欲了解更多信息，请访问。
Forward-looking Statements
前瞻性声明
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
这则新闻发布包含根据1995年《证券诉讼改革法案》定义的"前瞻性声明"。爱文思提醒读者，前瞻性声明基于管理层的期望与假设，并截至本新闻发布日期受到某些可能导致实际结果有所不同的风险和不确定性。这些风险和不确定性包括但不限于在公司向证券交易委员会提交的文件中确定的风险和不确定性。前瞻性声明仅反映我们在其指定日期的分析，爱文思不对更新或修订这些声明承担义务，除非法律要求。
Investor Relations and Media Contact:
投资者关系和媒体联系：
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
[email protected]
858-251-4400
Ira Duarte
执行副总裁，首席财务官
Heron Therapeutics，Inc.
[email protected]
858-251-4400
SOURCE Heron Therapeutics, Inc.
消息来源：Heron Therapeutics，Inc。
